Articles On Paradigm Biopharmaceuticals (ASX:PAR)

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

Paradigm Biopharmaceuticals (PAR) doses its first subject in the United Kingdom as part of its phase three clinical trial for the treatment of knee osteoarthritisThe first patient has been treated with Paradigm’s injectable pentosan polysul...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a decline. In afternoon trade, the benchmark index is down 0.6% to 6,774.4 points. Four ASX shares that are falling more than most today are listed below. Here’s why th...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Drug development company Paradigm Biopharmaceuticals [ASX:PAR] reported positive results for one of its clinical trials focused on osteoarthritis (OA). The post Paradigm Biopharmaceuticals [ASX:PAR] Spikes in Phase II Trial Results appeared...

Paradigm successfully meets primary endpoint of Phase 2 trial Immutep granted Fast Track designation by the FDA ImpediMed signs strategic partnership with GenesisCare Paradigm Biopharma (ASX:PAR) surged 19% this morning after announcing t...

The S&P/ASX 200 Index (ASX: XJO) is back on form on Tuesday and racing higher. In afternoon trade, the benchmark index is up 2.5% to 6,619.2 points. Four ASX shares that have climbed more than most today are listed below. Here’s why th...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has returned from its trading halt in style. In morning trade, the drug development company’s shares are up 19% to $1.50. Why is the Paradigm share price rocketing higher? Investor...

Small caps slip down 3.3%, and global markets look equally wobbly China’s manufacturing Purchasing Managers’ Index (PMI) actually grew in September  Alchemy Resources draws a ballot for some prospective lithium ground near big names in WA...

As nerves mount for players on both NRL Grand Final sides preparing to line up at Staiudm Australia on Sunday night, it’s worth remembering the myriad enterprises that enable sportspeople to leap higher and kick further – while also tending...

Paradigm Biopharmaceutical (PAR) has flagged a successful safety review of a phase two study of its pentosan polysulfate sodium (PPS) product in mucopolysaccharidosis type VI (MPS-VI) patientsThe company says the safety monitoring physician...

The S&P/ASX All Ordinaries Index (ASX: XAO) closed in the red on Friday, down 1.9% to just below 6,789 points. But as is often the case, a few ASX All Ords shares defied the index and ramped higher today. Let’s take a look. KMD Brand...

Paradigm Biopharmaceuticals (PAR) raises $66 million through a placement and entitlement offer to fund the development of its clinical trialsAdditionally, the money will support business and product development, as well as working capitalTh...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is enjoying a day in the green today after the company announced its yearly financial results for FY22. Shares in the ASX biotech company are up 2.34% at $1.31 in early afternoon t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,072.6 points. Four ASX shares that have failed to follow the market higher today ar...

Paradigm Biopharmaceuticals (PAR) taps investors for $66 million to fund developments into the 2024 calendar year The fully underwritten capital raise will comprise a $45.7 million institutional placement and a $20.3 million entitlement of...

Recent cap raising suggests biotechs may finally be making a comeback Mesblast annnounced a US$45m cap raise last week Today, Paradigm, Opthea, and Proteomics also announced fund raises Over the past year, the biotech sector has been caug...

The GPT Group (ASX: GPT) share price is making a commendable move upwards today following the release of its interim results for 2022. At the time of writing, shares in the diversified property group are 5.7% in the green. As a result, th...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. I have been entrusted...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is plummeting after coming out of a trading halt this morning. At the time of writing, the biopharmaceutical company’s shares are fetching at $1.45, down 26.95%. What’s drivi...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. When the market is do...

ASX 200 and small caps rise circa 1% Regional markets jump on strong leads, US inflation data Ragusa Metals: up 60% Local markets took off at the open, feeling a little of the excitement which took hold of Wall Street overnight. The bench...

Paradigm Biopharmaceuticals (PAR) enters into a trading halt ahead of a capital raise There is currently no details on how much the company is aiming to raise or where it plans to spend the money Under the halt, company shares will be paus...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is going nowhere today after the company requested a trading halt.  The Paradigm share price has rocketed from $1.05 per share on 28 July to $1.99 per share at Wednesday’s close...

Listed drug repurposing business Paradigm Biopharmaceuticals has put a big raise to investors, asking them to tip in $62 million while it waits for key trial results.

The Nickel Industries Ltd (ASX: NIC) share price closed lower on Monday amid a significant debt announcement by the mineral exploration company. Nickel Industries shares finished the day down 1.82% at $1.08 each after hitting an intraday l...

Drug developer Paradigm Biopharmaceuticals [ASX:PAR] rose more than 10% on Monday after releasing an update on its clinical program. The post Paradigm [ASX:PAR] Spikes on Clinical Program Update appeared first on Money Morning Australia.

It’s been a slow start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. As it stands today, the ASX 200 has risen by an anaemic 0.07% and is hovering around the 7,020 point mark. So let’s dig a little deeper into t...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up slightly to 7,017.1 points. Four ASX shares that are climbing more than most today are listed...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Even with the curren...

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. Warren Buffett has a...

The Paradigm Biopharmaceuticals Limited (ASX: PAR) share price is soaring today amid news the company will present its research at an international conference. Paradigm shares are trading at $1.92 each, up 11.63%, at the time of writing. E...

Wesfarmers Ltd (ASX: WES) shares are among the most popular ASX blue chip investments on the S&P/ASX 200 Index (ASX: XJO) today. This ASX 200 industrial and retailing conglomerate is now the ninth-largest share on the ASX 200 index by...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

The Mayne Pharma Group Ltd (ASX: MYX) share price is up 4.48% on Monday morning amid news the company has received US regulatory approval. Shares of Mayne Pharma are currently trading at 35 cents each after opening at 33.5 cents a share th...

The OZ Minerals Limited (ASX: OZL) share price has shot higher to be the best performer in the S&P/ASX 200 Index (ASX: XJO) at the time of writing. OZ Minerals shares are currently trading for $25.51 each, a 34.83% leap from their prev...

ShareCafeEvening Report: 13 July, 2022 by Melissa Darmawan   Australian shares lacked conviction as investors remained cautious ahead of the US inflation data. The index remained in a holding pattern as it jumped above and below the flat li...

Paradigm Biopharmaceuticals (PAR) enters into a corporate partnership with NFL Alumni Health The partnership will inform NFL Alumni members about osteoarthritis disease onset, current treatment options, and provide information about clinic...

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is in the green on Wednesday following the company’s latest announcement. At the time of writing, the biopharmaceutical company’s shares are fetching at $1.055 each, up 0.48%...

ShareCafeLunch Report: 13 July, 2022 by Melissa Darmawan   Australian stocks have lacked conviction today, shuffling above and below the flat line as investors weigh up the prospect of an aggressive rate hiking path to combat multi-year hig...

ShareCafeEvening Report: 6 July, 2022 by Lauren Evans   Australian shares spent the afternoon in the red as commodity prices plunged on recession fears. The energy sector tumbled 5.8 per cent, with materials down 5 per cent. Real estate was...

ResApp gets clearance from the US FDA Immutep is granted patent in Japan Paradigm Biopharma to commence Phase 3 trial ResApp Health (ASX:RAP) announced that SleepCheckRx has received 510(k) clearance as a prescription-only Software-as-a-M...

ShareCafeLunch Report: 6 July, 2022 by Melissa Darmawan   The Australian sharemarket has been choppy this morning, trading as low as 0.5 per cent before rebounding to a gain of 0.2 per cent to then fall again. Information technology shares...

Paradigm Biopharmaceuticals (PAR) activates its first trial site in the United Kingdom for a third-phase trial of its Zilosul treatment for knee osteoarthritis The news comes after the company received UK regulatory and ethics approvals to...

Paradigm Biopharmaceuticals’ (ASX:PAR) investment relations guy Simon White is a bit different to your average biotech corporate gun for hire, given he’s actually tried the remedy he is promoting. A footballer with the AFL’s Carlton Footbal...

Paradigm Biopharmaceuticals (PAR) completes recruitment for its phase two clinical trial for treating knee osteoarthritis (OA) The phase two study aims to evaluate the treatment of pentosan polysulphate sodium (PPS) against a placebo in 6...

Wall Street had its worst ever start to the year in 50 years New data suggests the US economy is losing steam The ASX 200 is set to open higher today Wall Street tumbled again overnight by 1%, ending June as its worst ever start to the ye...

ShareCafeEvening Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket closed at session lows and had its worst day in two weeks in a broad-based rout. At the closing bell, the S&P/ASX 200 was almost 2 per cent or 132 p...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

Paradigm Biopharmaceuticals (PAR) receives approval from IP Australia for a key patent application for its knee osteoarthritis treatment The patent is for the treatment of bone marrow pathologies with PAR’s pentosan polysulphate sodium (PP...